A Study of the Safety and Tolerability of ASP7317 in Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration
Last updated on July 2021Recruitment
- Recruitment Status
- Active, not recruiting
- Estimated Enrollment
- 150
Summary
- Conditions
- Age - Related Macular Degeneration
- Type
- Interventional
- Phase
- Phase 1
- Design
- Allocation: Non-RandomizedIntervention Model: Sequential AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 50 years and 125 years
- Gender
- Both males and females
Description
The study consists of the following periods: Screening (up to 45 days) and the Study Period (52 weeks post treatment). Screening and enrollment are temporarily halted due to COVID-19.
The study consists of the following periods: Screening (up to 45 days) and the Study Period (52 weeks post treatment). Screening and enrollment are temporarily halted due to COVID-19.
Tracking Information
- NCT #
- NCT03178149
- Collaborators
- Not Provided
- Investigators
- Study Director: Medical Director Astellas Institute for Regenerative Medicine